Eric Karas - 01 Jul 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role: Chief Commercial Officer
Signature: /s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol: SPRY
Transactions as of: 01 Jul 2025
Net transaction value: -$232,360
Form type: 4
Filing time: 03 Jul 2025, 16:21:24 UTC
Previous filing: 20 Jun 2025
Next filing: 05 Jan 2026
SEC filing: View on sec.gov

Key filing fact

Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 03 Jul 2025.

Key facts

This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
3 reported transactions and 1 derivative row are listed below.
Filing timestamp: 03 Jul 2025, 16:21.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: -$232,360.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001951287 Primary reporting owner

Karas Eric

Relationship: Chief Commercial Officer
Address: C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Signature: /s/ Kathleen Scott, Attorney-in-Fact
Signature date: 03 Jul 2025

Reported transactions

SPRY transaction

Common Stock

Options Exercise

Transaction value: $22,500
Shares: +15,000
Change %: +145%
Price: $1.50
Shares after: 25,315
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F1

SPRY transaction

Common Stock

Sale

Transaction value: $254,860
Shares: -15,000
Change %: -59%
Price: $16.99
Shares after: 10,315
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -2.7%
Price: $0.000000
Shares after: 544,588
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $1.50
Footnotes: F4

^* indicates a reported price that failed the local validity check.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
F2	The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
F3	The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4	Immediately exercisable.